- Home
- CBZ vs SLS Comparison
CBZ vs SLS Comparison
Compare CBZ & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CBZ | SLS |
|---|---|---|
| Founded | 1987 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.7B |
| IPO Year | 1996 | 2007 |
Fundamental Metrics
Financial Performance| Metric | CBZ | SLS |
|---|---|---|
| Price | $54.85 | $11.64 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $55.00 | $32.50 |
| AVG Volume (30 Days) | 882.7K | ★ 4.9M |
| Earning Date | 10-28-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 134.62 | 50.00 |
| EPS | ★ 2.83 | N/A |
| Revenue | ★ $922,003,000.00 | N/A |
| Revenue This Year | $2.36 | N/A |
| Revenue Next Year | $4.52 | N/A |
| P/E Ratio | $19.36 | ★ N/A |
| Revenue Growth | ★ 7.79 | N/A |
| 52 Week Low | $24.29 | $1.39 |
| 52 Week High | $56.41 | $15.88 |
Technical Indicators
Market Signals| Indicator | CBZ | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 69.95 | 42.98 |
| Support Level | $54.37 | $10.82 |
| Resistance Level | $54.89 | $12.53 |
| Average True Range (ATR) | 0.09 | 0.71 |
| MACD | -0.14 | -0.03 |
| Stochastic Oscillator | 68.97 | 29.67 |
Price Performance
Historical ComparisonAbout CBZ CBIZ Inc.
CBIZ Inc through its subsidiaries provides professional services advisors to middle-market businesses and organizations nationwide. Its business units have been aggregated into three practice groups: Financial Services, Benefits and Insurance Services, and National Practices. The company provides its services to various industries such as Banking & Financial Services, Commercial Real Estate, Construction, Health Care Manufacturing & Distribution NFP & Education, Private Client Services, Professional Services, Public Sector, and Technology & Life Sciences. It derives the maximum of its revenues from the Financial Services segment and geographically from the United States.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.